Passage Bio Adopts Key Proposals at Annual Meeting

Passage Bio ( (PASG) ) has provided an announcement.

On May 28, 2025, Passage Bio, Inc. held its 2025 Annual Meeting of Stockholders where key proposals were adopted, including the election of two Class II directors, Maxine Gowen, Ph.D., and Dolan Sondhi, Ph.D., to serve three-year terms. Additionally, the stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for 2025 and approved a potential reverse stock split of common stock, with the exact ratio to be determined by the Board before the end of the year. These decisions could impact the company’s governance and financial strategies moving forward.

The most recent analyst rating on (PASG) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.

Spark’s Take on PASG Stock

According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.

Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.

To see Spark’s full report on PASG stock, click here.

More about Passage Bio

Passage Bio, Inc. operates in the biotechnology industry, focusing on developing transformative therapies for rare monogenic central nervous system disorders.

Average Trading Volume: 252,539

Technical Sentiment Signal: Sell

Current Market Cap: $22.36M

For detailed information about PASG stock, go to TipRanks’ Stock Analysis page.